Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 1.00 |
| ▸ | PDE2A | O00408 | 1/20 | 0.79 |
| ▸ | PKLR | P30613 | 1/20 | 0.69 |
| ▸ | MAOA | P21397 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.61 |
| ▸ | PPARG | P37231 | 1/20 | 0.58 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.58 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.57 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401241 | 1.00 | NPSR1 (1.00) | NPSR1RXFP1PDE2APKLRMAOA | |
| SCHEMBL29369247 | 1.00 | NPSR1 (1.00) | NPSR1RXFP1PDE2APKLRMAOA | |
| Hydrochloric Acid SCHEMBL30777912 | 0.98 | NPSR1 (0.96) | NPSR1RXFP1PDE2APKLRMAOA | |
| SCHEMBL29401099 | 0.89 | PDE2A (1.00) | NPSR1RXFP1PDE2APKLRMAOA | |
| SCHEMBL29368885 | 0.89 | PDE2A (1.00) | NPSR1RXFP1PDE2APKLRMAOA | |
| SCHEMBL803408 | 0.89 | PDE2A (1.00) | NPSR1RXFP1PDE2APKLRMAOA | |
| SCHEMBL16663940 | 0.89 | PDE2A (0.85) | NPSR1RXFP1PDE2APKLRMAOA | |
| SCHEMBL24922443 | 0.87 | NPSR1 (0.77) | NPSR1RXFP1PDE2APKLRMAOA | |
| SCHEMBL31408197 | 0.87 | NPSR1 (0.77) | NPSR1RXFP1PDE2APKLRMAOA | |
| SCHEMBL29466712 | 0.87 | NPSR1 (0.77) | NPSR1RXFP1PDE2APKLRMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| CN-114760996-A | Direct AMPK activator compounds in combination with indirect AMPK activator compounds, compositions, methods, and uses thereof | 雀巢产品有限公司 | 2022-07-15 | — | — | CN | claimed |
| WO-2022040321-A1 | PROTECTION AGAINST CORONAVIRUS INFECTION BY EXTRACTS AND EXTRACT COMPONENTS | NATREON, INC. (US) | 2022-02-24 | — | — | WO | claimed |
| US-20220054575-A1 | PROTECTION AGAINST CORONAVIRUS INFECTION BY EXTRACTS AND EXTRACT COMPONENTS | NATREON, INC. (US) | 2022-02-24 | — | — | US | claimed |
| WO-1996031206-A2 | FLAVONES AND COUMARINS AS AGENTS FOR THE TREATMENT OF ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1996-10-10 | — | — | WO | claimed |
| US-12473269-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2025-11-18 | — | — | US | disclosed |
| US-20250283008-A1 | FLUORINE-CONTAINING ETHER COMPOUND, LUBRICANT FOR MAGNETIC RECORDING MEDIUM, AND MAGNETIC RECORDING MEDIUM | RESONAC CORPORATION (JP) | 2025-09-11 | — | — | US | disclosed |
| US-12358884-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2025-07-15 | — | — | US | disclosed |
| US-12351567-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2025-07-08 | — | — | US | disclosed |
| EP-4555997-A1 | WATER-SOLUBLE COMPOSITION COMPRISING UROLITHIN | Science4Beauty Sp. z o.o. (PL) | 2025-05-21 | — | — | EP | disclosed |
| WO-2025078645-A1 | COSMETIC USE OF AT LEAST UROLITHIN B OR C ON A SENSITIVE SKIN | L'OREAL (FR) | 2025-04-17 | — | — | WO | disclosed |
| WO-2024177047-A1 | FLUORINATED ETHER COMPOUND, LUBRICANT FOR MAGNETIC RECORDING MEDIA, AND MAGNETIC RECORDING MEDIUM | 株式会社レゾナック | 2024-08-29 | — | — | WO | disclosed |
| US-20120264819-A1 | Therapeutic Uses of Urolithins | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-18 | — | — | US | disclosed |
| US-8183282-B2 | Therapeutic uses of urolithins | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090326057-A1 | THERAPEUTIC USES OF UROLITHINS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2009-12-31 | — | — | US | disclosed |
| EP-2068864-A2 | THERAPEUTIC USES OF UROLITHINS | The Regents of the University of California (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2007127263-A2 | THERAPEUTIC USES OF UROLITHINS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2004073612-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO. INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-1996031206-A2 | FLAVONES AND COUMARINS AS AGENTS FOR THE TREATMENT OF ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358884-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | NPSR1 3213/4885RXFP1 3981/4885PDE2A 1089/4885 |
| US-20090326057-A1 | THERAPEUTIC USES OF UROLITHINS | UROD, UTS2R, PLAU | NPSR1 1713/4885RXFP1 1308/4885PDE2A 1882/4885 |
| US-12351567-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | NPSR1 3213/4885RXFP1 3981/4885PDE2A 1089/4885 |
| US-20120264819-A1 | Therapeutic Uses of Urolithins | UROD, UTS2R, PLAU | NPSR1 1713/4885RXFP1 1308/4885PDE2A 1882/4885 |
| US-12473269-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | NPSR1 3213/4885RXFP1 3981/4885PDE2A 1089/4885 |
| US-20250283008-A1 | FLUORINE-CONTAINING ETHER COMPOUND, LUBRICANT FOR MAGNETIC RECORDING MEDIUM, AND MAGNETIC RECORDING MEDIUM | CHRM5, CHRM2, AFF4 | NPSR1 303/4885RXFP1 19/4885PDE2A 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.